, /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, updated the Phase efficacy and safety results of IBI939 (anti-TIGIT antibody) combined with sintilimab (anti-PD-1 antibody) in previously…Read More
Innovent Updates Phase 1b Data of IBI939 AntiTIGIT Monoclonal Antibody Combined with Sintilimab in Previously Untreated PDL1selected NSCLC at the 2023 ASCO Annual Meeting
